The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on implementation of NICE TA1022: Ublituximab for treating relapsing multiple sclerosis (30 day TA).
Comments are welcomed from across the system, including residents and patients of the NENC. Comments will be returned to the medicines committee, or its sub-committee, and used to inform implementation of the decisions in NENC.
This consultation will run for 2 weeks and will close at 5pm on Thursday 2nd January 2025. Take part by visiting the consultations page.